NCT06699420 Qishenyiqi Dripping Pill for Coronary Microvascular Disease
| NCT ID | NCT06699420 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Coronary Microvascular Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 162 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 162 participants in total. It began in 2023-11-08 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
Eligibility Criteria
Inclusion Criteria: * Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; * Coronary normal or stenosis \< 20%; * Ischemic depression in ST segment during resting or exercise; * Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0; * Subjects or their guardians agreed to participate in this study. Exclusion Criteria: * Previous myocardial infarction or PCI or CABG treatment; * A history of heart failure; * Severe arrhythmia; * Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm; * Familial hypercholesterolemia; * Takayasu arteritis, Kawasaki disease or coronary artery malformation; * Pregnant or nursing, or having the intention to give birth within one year; * Hepatic or renal dysfunction; * Allergic to contrast agents or traditional Chinese medicines; * Patients who participated in clinical research of other drugs within 3 months before being selected.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06699420 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Coronary Microvascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06699420 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06699420 currently recruiting?
Yes, NCT06699420 is actively recruiting participants. Contact the research team at panda.how@sdu.edu.cn for enrollment information.
Where is the NCT06699420 trial being conducted?
This trial is being conducted at Jinan, China, Jinan, China, Jinan, China.
Who is sponsoring the NCT06699420 clinical trial?
NCT06699420 is sponsored by Qilu Hospital of Shandong University. The trial plans to enroll 162 participants.